Jan 28 2008, 4:36 AM EST
PRNEWSWIRE
To date, Profectus BioSciences has a unique relationship with the Institute of Human Virology (www.IHV.org), along with other academic and government institutions to gain access to breakthrough technologies focused on the treatment and prevention of AIDS/HIV. Currently, the Company has five technology platforms and two commercialization partners to progress the development of its AIDS vaccine for human and veterinary use. The Company plans to work with other commercialization partners to progress the other four promising technology platforms in the treatment of AIDS/HIV.
O'Brien has extensive global experience in business development, sales, licensing, and R&D at biotech and large pharma companies. He comes to Profectus BioSciences from Solstice Neurosciences Inc., where he served as president and chief executive officer since 2004. During his tenure at Solstice, O'Brien increased key sales by 90 percent, opened the EU market with new partners and patents, addressed unsettled patent issues and expanded the clinical development program to include six investigational new drugs (INDs).
Previously, O'Brien worked with AstraZeneca USA as vice president of
commercial operations for emerging brands, and as vice president and therapy
area leader for the respiratory and inflammation business unit. As the area
leader, O'Brien was responsible for research and development, marketing and
sales of the products in the area. From 1987 through 2001, he held various
management positions at AstraZeneca in global and domestic roles in the USA,
O'Brien succeeds Joseph F. Berardino, who established a solid foundation for the company in its early years by putting the business platform in place to secure funding for the Company. Joe also played a critical role in solidifying partnerships to progress the five technology platforms. The board of directors credits Berardino for the company's emergence as a successful biotechnology business. Berardino will continue with the company as a director.
"I have enjoyed working with the founding scientists, management, board and staff of the company to bring Profectus to where it is today. The opportunities before us are immense and the company is on solid footing to make the most of our science and technology. Shawn is the ideal leader to take the helm as CEO," said Berardino.
In addition, the company's board of directors announced that Donald R.
Caldwell will serve as its chairman. Caldwell, who initially joined the
Profectus board of directors in
Prior to founding Cross Atlantic Capital Partners, Caldwell was president
and chief operating officer of Safeguard Scientifics and served in a number of
executive and financial positions, including chief administrative officer of a
predecessor company of Cambridge Technology Partners, Inc. and president of
Atlantic Financial. Earlier, Caldwell earned his CPA and was a partner in the
national office of
ADVERTISEMENT
INTERVIEW:
NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates
...MORE
NewsArticles BlogsADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More News
Listen
Save
Comment
View All